Table 1.

Participant characteristics

	FoG−	FoG+	p-value
N (female)	15(4)	12(5)	0.43^α
Age	66.35(6.02)	65.4(7.99)	0.73
UPDRS-III	24.14(11.78)	28.88(15.34)	0.38
NFoG-Q	0	4.4(6.03)	--
Disease Duration	6.38(4.75)	11.32(6.76)	*0.04*
MiniBEST	23.20(3.76)	22.08(3.55)	0.44
MoCA	27.47(3.04)	25.67(3.37)	0.16
Levodopa	598.67(228.41)	545.45(283.24)	0.6
Fatigue (absolute)^‡	2.41(1.38)	2.47(1.59)	0.92
Fatigue (change)^#	1.21(0.99)	0.64(1.03)	0.19
Sleep (hours)^**	6.57(1.53)	6.44(1.32)	0.82

^α

Fisher’s exact test. All other comparisons are independent sample t-tests.

^‡

Fatigue measured on a 1–10 scale;

Change in fatigue over the course of training;

^**

Hours of sleep after the training session.

FoG−: People with PD not experiencing freezing of gait; FoG+: People with PD who experience freezing of gait; MoCA: Montreal Cognitive Assessment; MiniBEST: Mini Balance Evaluation Systems Test; UPDRS-III: Part III (motor score) of the Unified Parkinson’s disease rating scale; NFoGQ: New Freezing of Gait Questionnaire